<DOC>
	<DOCNO>NCT01473381</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , tolerability 2 fix dose level vilazodone compare placebo patient major depressive disorder .</brief_summary>
	<brief_title>Safety Efficacy Vilazodone Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Vilazodone Hydrochloride</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Men woman , 1870 year age . Currently meet Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) criteria Major Depressive Disorder . The patient 's current major depressive episode must least 8 week longer 12 month duration . Women pregnant , woman breastfeed study , woman childbearing potential practicing reliable method birth control . Patients history meeting DSMIVTR criterion : Any manic , hypomanic mixed episode , include bipolar disorder substanceinduced manic , hypomanic , mixed episode Any depressive episode psychotic catatonic feature Panic disorder without agoraphobia Obsessivecompulsive disorder Schizophrenia , schizoaffective , psychotic disorder Bulimia anorexia nervosa Presence borderline personality disorder antisocial personality disorder Mental retardation , dementia , amnesia , cognitive disorder . Patients consider suicide risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Depression</keyword>
</DOC>